TransCode Therapeutics, Inc. (RNAZ) News
Follow TransCode Therapeutics, Inc. (RNAZ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Transcode reports durable disease control and no DLTs with TTX-MC138 in Phase 1a update
Transcode reported continued disease stabilization and extended treatment duration with TTX-MC138 in its Phase 1a trial.Key Highlights:Original SEC Filing: Transcode Therapeutics, Inc. [ RNAZ ] - 8-K - Sep. 28, 2026This
REGULATION | Sep 28, 2026, 12:25 PM UTC
M
TransCode Therapeutics wins Australia notice acceptance and Japan patent
TransCode Therapeutics received an Australian Notice of Acceptance and a granted Japanese patent covering RNA-based cancer therapies and delivery platforms, reinforcing its IP for immuno-oncology.
EQUITY | Sep 22, 2026, 12:05 PM UTC
L
RNAZ - TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
RNAZ - TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
NEWS | Sep 22, 2026, 12:04 PM UTC
L
Thomas A. Fitzgerald resigns as CFO of TransCode; John Tattory named interim CFO
TransCode announced that Thomas A. Fitzgerald resigned as Chief Financial Officer and director, effective September 9, 2026, and that John Tattory was appointed Interim Chief Financial Officer effective the same date.Ori
REGULATION | Sep 11, 2026, 09:04 PM UTC
L
TransCode Therapeutics appoints John Tattory interim CFO
TransCode Therapeutics Inc said it has appointed John Tattory as interim CFO. The company is listed on the Nasdaq under ticker RNAZ.
EQUITY | Sep 10, 2026, 08:26 PM UTC
L
Transcode Therapeutics CFO Fitzgerald to resign as director
Fitzgerald will resign as CFO and as a director, effective immediately at Transcode Therapeutics.
EQUITY | Sep 10, 2026, 08:17 PM UTC
L
Transcode Therapeutics names John Tattory interim CFO
EQUITY | Sep 10, 2026, 08:16 PM UTC
L
Transcode Therapeutics CFO Tom Fitzgerald to retire
MACRO | Sep 10, 2026, 08:16 PM UTC
L
TransCode Therapeutics CFO Tom Fitzgerald to retire; John Tattory interim CFO
Tom Fitzgerald, Chief Financial Officer, will retire. John Tattory will become Interim Chief Financial Officer, according to TransCode Therapeutics, Inc.
EQUITY | Sep 10, 2026, 08:10 PM UTC
L
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the ongoing Phase 2a color
EQUITY | Sep 03, 2026, 01:00 PM UTC